Genetic Analysis
- Company typePublic
- Founded2008
- HeadquartersOslo, Norway
- Headcount11–50
- GTM typeB2B
- OfferingServices
Genetic Analysis firmographics
Firmographics- Name
- Genetic Analysis
- Legal name
- Genetic Analysis AS
- Website
- https://genetic-analysis.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Genetic Analysis industry classification
Industry- Product category
- Microbiome Diagnostics
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH)
- akta.pro secondary industries
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
Keywords
Where Genetic Analysis is headquartered
LocationHeadquarters
- HQ city
- Oslo
- HQ country
- Norway
- HQ region
- Europe
Offices2 records
Markets served
Genetic Analysis business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Others
Revenue model
- GA-map® Dysbiosis Test Reagent Kit Sales: Sale of CE-marked reagent kits to diagnostic laboratories for their own use on Luminex instruments. Recurring revenue from reagent kit sales as labs perform tests. The company experienced 37% growth in reagent kit sales YTD December 2024 compared to 2023, and 13% growth in Q4 2025 reagent kit sales.
- Service Laboratory Testing: GA analyzes samples at its Oslo service laboratory and sends encrypted reports back to routine diagnostic laboratories. Fecal samples are collected locally, assembled by laboratories, and sent batchwise for analysis. This model generates revenue per test performed.
- Ferring Collaboration (MHI GutHealth): Revenue from collaboration with Ferring Pharmaceuticals to develop and launch the GA-map® MHI GutHealth test. GA has exclusive commercialisation rights with no obligations to pay running royalties or milestones to Ferring. Revenue will be generated based on number of tests sold.
- Thalys Partnership (China Market): Supply of reagent kits to Thalys Medical Technology Group for Chinese Consumer Health market testing. Revenues generated based on number of tests sold through the D2C platform.
- IBD Precision Dx Development: Development of diagnostic test for predicting disease course in ulcerative colitis patients, conducted in collaboration with Scandinavian university hospitals and funded by the Research Council of Norway. Expected to serve as additional growth driver upon launch in H1-26.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | GA-map Dysbiosis Test Lx - For diagnostic labs implementing GA-map technology |
| Transaction based/ take rate | Pay-as-you-go | Service Laboratory Testing - GA performs analysis for customers |
| Unit Pricing | Pay-as-you-go | GA-map MHI GutHealth - Research Use Only assay |
Go-to-market motion4 records
Distribution channels7 records
Marketing channels6 records
Genetic Analysis product offering
Product offeringCore offering
Genetic Analysis AS operates the GA-map® platform, a CE-marked IVD molecular diagnostic system for gut microbiota profiling. The company develops, manufactures, and sells reagent kits and assay protocols for use on standard Luminex instruments, enabling diagnostic laboratories to identify dysbiosis in patients with IBS and IBD. In parallel, it runs a centralized GA-map® Service Laboratory in Oslo and licenses its proprietary algorithm and AI-assisted AInsight interpretation software to support clinical decision-making and pharmaceutical companion-diagnostics programs.
Product overview
Genetic Analysis offers a platform-plus-products architecture centered on the GA-map® technology platform for microbiome diagnostics. The core platform consists of the GA-map® Dysbiosis Test Lx, a CE-marked IVD test for gut microbiota profiling in IBS/IBD patients that runs on Luminex instruments, and the GA-map® COVID-19 Fecal Test Kit. The reagent kit products (GA-map® Dysbiosis Test Reagent Kit, COVID-19 Reagent Kit) enable labs to run tests on-site, while the GA-map® Service Laboratory offers centralized testing. Additional modules include GA-map® MHI GutHealth (with Ferring Pharmaceuticals), GA-map® Discovery (research market), GA-map® IBD Precision Dx (in development), and AInsight (AI-assisted interpretation). The portfolio spans clinical diagnostics, clinical research, and companion diagnostics applications.
Differentiator
Problem solved
Functional benefit
Brands
- GA-map: Proprietary diagnostic technology platform for characterization of the human microbiome, including probe-based gut microbiota tests on Luminex instruments with standardized dysbiosis testing for IBS and IBD patients.
Products and services
- GA-map® Dysbiosis Test Lx A CE-marked IVD molecular diagnostic test for profiling gut microbiota dysbiosis in patients with IBS and IBD, designed to be run on standard Luminex bead-based instruments in routine diagnostic laboratories. It is the first CE-marked IVD test for gut microbiota dysbiosis and is used by clinical labs needing a reproducible, regulatory-cleared microbiome assay.
- GA-map® Dysbiosis Reagent Kit A CE-IVD marked reagent kit (consumable) that enables diagnostic laboratories to perform the GA-map® Dysbiosis Test on their existing Luminex instruments. Sold as a recurring consumable product, it forms the core reagent revenue stream for Genetic Analysis.
- GA-map® COVID-19 Fecal Test Kit A PCR-based fecal test kit for the detection of SARS-CoV-2 in stool samples, developed and launched in response to the COVID-19 pandemic. It enables laboratories to perform non-invasive COVID-19 testing and to study viral persistence in the gut.
- GA-map® COVID-19 Reagent Kit A qPCR reagent kit (consumable) that supports the GA-map® COVID-19 Fecal Test workflow for SARS-CoV-2 detection in stool samples. Sold to diagnostic laboratories as a recurring consumable kit.
- GA-map® MHI GutHealth A Research-Use-Only (RUO) gut health profiling assay that allows researchers and clinical investigators to characterize gut health using the GA-map® platform on Luminex instruments. It serves academic and translational research customers who do not require an IVD-marked test.
- GA-map® Discovery Reagent Kit A research-use reagent kit targeting more than 170 bacteria, designed for research and discovery applications that require broad bacterial coverage in a single workflow. It supports academic and industrial microbiome research projects using the GA-map® chemistry.
- GA-map® Service Laboratory A centralized diagnostic testing service operated from Oslo, Norway, that performs the GA-map® Dysbiosis Test on behalf of customers who prefer outsourced sample testing. It supports laboratories and clinicians that want standardized gut microbiota profiling without running the assay in-house.
- GA-map® AInsight An AI-powered interpretation platform integrated into the GA-map® product line. AInsight uses a Large Language Model (LLM) to assist clinicians and laboratory customers in interpreting GA-map® test results, drawing on the proprietary Bacteria Compendium and dysbiosis index outputs from the algorithm.
Quantifiable outcome
- 37% growth in GA-map Dysbiosis Test reagent kit sales in 2024 compared to 2023
- +4 more outcomes
Companies that use Genetic Analysis
Customer profileNamed customers12 records
Segments6 records
Ideal customer profiles4 records
Genetic Analysis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability3 records
Feature6 records
Genetic Analysis partnerships and signals
Strategic signalPartnerships
20 partnerships are on record, tiered major, flagship, core, standard and minor.
- Pangea Laboratory LLCmajorUS partner for launch of GA-map MHI GutHealth in the USA market.
- Ferring PharmaceuticalsflagshipCollaboration to develop and launch GA-map MHI GutHealth rapid diagnostic test combining GA's PCR platform with Ferring's Microbiome Health Index biomarker. GA has exclusive commercialisation rights with no royalties or milestones to Ferring. Test launched H1-2025 as Research Use Only product.
- ProkarimimajorLaunched DTC platform for Gut Microbiome testing in Norway powered by GA-map technology.
- Thalys Medical Technology GroupflagshipLaboratory Developed Test agreement for Chinese market using GA-map technology. Thalys uses Shanghai-based Independent Clinical Lab to develop and distribute tests. April 2025 launch of consumer health microbiome test via D2C mobile software platform.
- Eurofins ADME BIOANALYSESmajorService agreement with CRO to offer GA-map Dysbiosis Test to pharmaceutical and clinical research customers. First CRO to offer GA-map microbiome test, enhancing Eurofins' microbiome service offering.
- Luminex InccoreIndustrial partnership for technology platform. GA-map tests are designed for use on Luminex instruments (Luminex 200 and MAGPIX), utilizing xMAP Technology for multiplexed detection of bacteria targets.
- Bio-Rad IncmajorUS distribution partner for GA-map products. Bio-Rad also participated as subscriber in May 2025 directed share issue with NOK 4,693,500 investment.
- Eagle BioSciences IncstandardUS distribution partner for GA-map microbiome products in North America.
- BIOHIT OyjstandardFinnish distributor for GA-map products in Finland.
- BIOHIT HealthCare LtdstandardUK distributor for GA-map products.
- BIOHIT HealthCare SrlstandardItalian distributor for GA-map products.
- ARIUM Sistemas de Diagnóstico Lda.standardPortuguese distributor for GA-map products.
- Oslo University HospitalcoreCollaborating partnership in Scandinavia for clinical research and product development related to GA-map technology and microbiome diagnostics.
- Sahlgrenska Academy (University of Gothenburg)coreSwedish academic research partner collaborating on microbiome research and GA-map technology development.
- Skåne University Hospital (Lund University)coreSwedish collaborating partnership for clinical research and microbiome diagnostics development.
- Haukeland University HospitalcoreNorwegian hospital partner and current partner on GA-map COVID-19 Fecal Test project.
- Helse-FonnaminorNorwegian healthcare partner collaborating on microbiome research.
- UNN (University Hospital of North Norway)minorNorwegian hospital partner for microbiome research collaboration.
- Nordsjællands HospitalminorDanish hospital collaborating partner for microbiome research.
- Helsinki University HospitalminorFinnish hospital collaborating partner for microbiome research.
Scale indicators10 records
Recent moves7 records
Expansion highlights7 records
Genetic Analysis competitors and assessment
Company assessmentDirect peers
- Microba Life Sciences: Australia-based gut microbiome testing and analysis company offering metagenomic profiling and microbiome insights to clinicians, researchers, and consumers. Directly comparable to GA in targeting the gut microbiome diagnostics opportunity, though Microba leans on shotgun metagenomics rather than GA's probe-based PDT approach.
- ZOE: Consumer-focused gut microbiome testing and personalised nutrition company using shotgun metagenomics to deliver diet guidance. Comparable in addressing the same gut-health clinical question for IBS/IBD-adjacent consumers, but operating in a pure D2C, consumer subscription model versus GA's lab-channel core.
- Viome Life Sciences: Direct-to-consumer microbiome testing company using metatranscriptomic analysis to provide personalised nutrition and supplement recommendations. Competes with GA's consumer-channel ambitions (e.g. Thalys in China, Prokarimi in Norway), although Viome is consumer-led while GA's centre of gravity is clinical labs.
- DayTwo: Personalised nutrition company that provides gut-microbiome-based dietary recommendations for managing metabolic conditions. Overlaps with GA's nutritionist customer segment and gut-health use case, but DayTwo is more consumer/employer-benefit oriented and uses NGS-based analysis.
Emerging players
- CosmosID: Microbiome genomics services company providing NGS-based pathogen detection, microbiome profiling, and bioinformatics to clinical, industrial, and research customers. Compares to GA's research-market (GA-map Discovery) and service-lab offering, though CosmosID operates a different technology stack.
- MaaT Pharma: Late-stage clinical microbiome therapeutics company developing FMT-based and defined-consortium therapies, including for rCDI. Comparable to GA in addressing the same gut-microbiome clinical rationale (including rCDI, the validation population for MHI GutHealth), but MaaT is on the therapeutic rather than diagnostic side.
- Seres Therapeutics: Microbiome therapeutics company with an approved rCDI product (Vowst) and other pipeline programmes. Comparable in addressing the same clinical opportunity as GA's MHI GutHealth rCDI assay and companion-diagnostics franchise, but on the drug rather than diagnostic side.
- Rebiotix (a Ferring company): Ferring-owned microbiome therapeutics business that developed the RBX2660 (Rebyota) FMT therapy for rCDI. Highly comparable in addressing the rCDI market that underpins GA's MHI GutHealth collaboration with Ferring, and the parent relationship makes Rebiotix a critical counterparty for GA's franchise.
Broad incumbents
- Genova Diagnostics: Specialty clinical laboratory offering comprehensive stool-based and other functional medicine diagnostics to clinicians and consumers globally. Comparable as a broader-spectrum lab that competes with GA's dysbiosis test in the gastroenterology and functional-medicine prescribing workflow, though Genova offers a much wider test menu.
- Bio-Rad Laboratories: Global life science tools and clinical diagnostics company and GA's US distribution partner and largest investor. Comparable as a broad incumbent in clinical diagnostics and microbiome research reagents, while also being a strategic counterparty whose commercial decisions materially shape GA's US trajectory.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Genetic Analysis social profiles
Digital presenceGenetic Analysis compliance and trust
Trust signalCompliance2 records
Genetic Analysis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genetic Analysis leadership team
Management profileNumber of profiles
Profiles12 records
Genetic Analysis funding detail
Funding detailFunding overview
Funding rounds3 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genetic Analysis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genetic Analysis
What does Genetic Analysis do?
Genetic Analysis AS operates the GA-map® platform, a CE-marked IVD molecular diagnostic system for gut microbiota profiling. The company develops, manufactures, and sells reagent kits and assay protocols for use on standard Luminex instruments, enabling diagnostic laboratories to identify dysbiosis in patients with IBS and IBD. In parallel, it runs a centralized GA-map® Service Laboratory in Oslo and licenses its proprietary algorithm and AI-assisted AInsight interpretation software to support clinical decision-making and pharmaceutical companion-diagnostics programs.
Is Genetic Analysis a public or private company?
Genetic Analysis is a public company. It is classified as public and is currently operating.
When was Genetic Analysis founded?
Genetic Analysis was founded in 2008. It employs 11 to 50 people.
Where is Genetic Analysis based?
Genetic Analysis is headquartered in Oslo, Norway, in the Europe region.
How does Genetic Analysis make money?
Five revenue lines are on record. GA-map® Dysbiosis Test Reagent Kit Sales are the primary driver. The others are service Laboratory Testing, ferring Collaboration (MHI GutHealth), thalys Partnership (China Market) and IBD Precision Dx Development.
Who are Genetic Analysis's main competitors?
Direct peers on record are Microba Life Sciences, ZOE, Viome Life Sciences and DayTwo. Emerging players are CosmosID, MaaT Pharma, Seres Therapeutics and Rebiotix (a Ferring company). Broad incumbents are Genova Diagnostics and Bio-Rad Laboratories.
Does Genetic Analysis have an API?
No public API is recorded for Genetic Analysis.
What industry is Genetic Analysis in?
Genetic Analysis's product category is Microbiome Diagnostics. Its primary akta.pro industry code is HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 621511 and its SIC code is 8071.